Intravesical Adjuvant Treatment in Superficial Bladder Cancer

REFERENCES

• Bouffioux C, Denis L, Kurth KH et al. Quelle chimiothérapie intravésical pour quelle tumeur de vessie en 1988? J (Franc) d'Urol 1988; 94: 5–6, 251–260.
   Google Scholar
• Pavone-Macaluso M. Diagnosis and treatment of superficial bladder tumors. Biomedical topics, Farmitalia Carlo Erba, Milano, 1982.
   Google Scholar
• Holtl W, Hasun R, Albrecht W. Prospective randomized trial to evaluate high versus low dose Interferon alfa2b versus conventional therapy in prevention of recurrence of superficial TCC of the urinary bladder. Monograph. Current role of Alpha Ifn in the treatment of bladder cancers. Ed. Schering-Plough, 1991, p 17.
   Google Scholar
• Calais da Silva F. Mitoxantrone. A phase II chemore-section study in Ta/Tl bladder cancer. Abst. AUA meeting 1989. J Urol 1989; 141: 398A (no 925).
   Google Scholar
• Jurincic, Klippel. Randomized prospective study comparing KHL versus MMC in patients with superficial bladder carcinoma (Ta, Tl) after complete TUR. J Urol 1988; 139: 723–726.
   PubMed Web of Science ®Google Scholar
• Mellicow M. Histologic study of vesical urothelium intervening between gross neoplasms in total cystectomy. J Urol 1952; 68: 261.
   PubMedGoogle Scholar
• Steg A, Bioteux JP, Boccon-Gibod D, Debre B. The natural history of in situ bladder carcinoma. An experience with 18 “untreated” patients. Abstract 282, AUA Meeting, Atlanta, 1985. J Urol 1985; 133: 4/2, 184A.
   Google Scholar
• Althausen A, Prout G, Daly J. Non invasive papillary carcinoma of the bladder associated with carcinoma in situ. J Urol 1976; 116: 575.
   PubMed Web of Science ®Google Scholar
• De Kernion J, Mukamel E, Kaufman J. The management of diffuse carcinoma in situ of the bladder with intravesical therapy. Abstract Book, XXe Congress SIU, Vienna 1985, no 484.
   Google Scholar
• Fluchter SH, Harzmann R, Bichler KH. Local Mitomycin-C therapy of transitional cell carcinoma of the bladder serum resorption study and clinical results, in Mitomycin-C. Current Impact on Cancer Chemotherapy (Ogawa M, Rozencweig M, Staquet MJ, eds.) pp 143–152, Excerpta Medica, Amsterdam, 1982.
   Google Scholar
• Harrison GSM, Green D, Newling DWW et al. A phase II study of intravesical Mitomycin C in the treatment of superficial bladder cancer. Br J Urol 1983; 55: 676–679.
   PubMedGoogle Scholar
• Issell BF, Prout GR, Soloway MS et al. Mitomycin-C intravesical therapy in non-invasive bladder cancer after failure on Thiotepa. Cancer 1984; 53: 1025.
   PubMed Web of Science ®Google Scholar
• Soloway MS. Treatment of superficial bladder cancer with intravesical Mitomycin-C: analysis of immediate and long term response in 70 patients. J Urol 1985; 134: 1107–1109.
   PubMed Web of Science ®Google Scholar
• Bouffioux C. Experience with Mitomycin-C in superficial bladder cancer: Preliminary results of intravesical administration to prevent recurrences: Controlled Clinical Trials in Urologic Oncology (Denis L, Murphy GP, Prout GR, Schröder F, eds), Raven Press, New York, 1984; 279–280.
   Google Scholar
• Powell CS, Williams SL. Results of treatment of TIS, Ta and Tl superficial bladder tumors with Mitomycin-C and Epodyl. Presentation at 3rd Congress of International Society of Urology-Endoscopy, Karlsruhe, August 26–30, 1984.
   Google Scholar
• Koontz WW, Heney NM, Soloway MS. Mitomycin for patients who failed on Thiotepa. Urology 26, 1985; suppl 4, 30–31.
   Google Scholar
• Jauhiainen K, Sotaranta M, Permi J et al. Effect of Mitomycin-C and Doxorubicin instillation on carcinoma in situ of the urinary bladder. Eur Urol 1986; 12: 3237.
   Google Scholar
• Lucero SP, Wise HA. Intravesical therapy of low stage bladder carcinoma with Mitomvcin-C. J Urol. AUA 135, 1986; 329: 186A.
   Google Scholar
• Hetherington JW, Newling DWW, Robinson MRG. Intravesical Mitomycin-C for the treatment of recurrent superficial bladder tumors. Br J Urol 1987; 59: 239–241.
   PubMedGoogle Scholar
• Edsmyr F, Berlin T, Boman J, Esposti PL, Gustafson H, Wikström M, Duchek M, Eksborg S. Intravesical therapy with Adriamycin in patients with superficial bladder tumors. Proc First Conf on Treatment of Urinary Tract Tumors with Adriamycin. Tokyo: Kyowa Hakko Kogyo, 50, 1979.
   Google Scholar
• Jackse G, Hofstadter F, Marberger H. Intracavitary Doxorubicin hydrochloride therapy for carcinoma in situ of the bladder. J Urol 1981; 125: 185.
   PubMedGoogle Scholar
• Glashan RW. Treatment of carcinoma in situ of the bladder with Doxorubicin (Adriamycin). Cancer Chemother Pharmacol 11 (suppl): S35; 1983.
   PubMedGoogle Scholar
• Brosman SA. The use of bacillus Calmette-Guérin in the therapy of bladder carcinoma in situ. The Journal of Urology, 1985; 134: 36–39.
   PubMedGoogle Scholar
• De Kernion JB, et al. The management of superficial bladder tumors and carcinoma in situ with intravesical bacillus Calmette-Guérin. J Urol 1985; 133: 598–601.
   PubMedGoogle Scholar
• Herr HW, et al. Long-term effect of intravesical bacillus Calmette-Guérin on flat carcinoma in situ of the bladder. J Urol 1986; 135: 265–267.
   PubMed Web of Science ®Google Scholar
• Hudson MA, et al. Single course versus maintenance bacillus Calmette-Guérin therapy for superficial bladder tumors: a prospective, randomized trial. J Urol 1987; 138; 295–298.
   PubMed Web of Science ®Google Scholar
• Kelley DR, et al. Prognostic value of purified protein derivative skin test and granuloma formation in patients treated with intravesical bacillus Calmette-Guérin. J Urol 1986; 135: 268–271.
   PubMed Web of Science ®Google Scholar
• Lamm DL. Bacillus Calmette-Guérin immunotherapy for bladder cancer. J Urol 1985; 134: 40–47.
   PubMed Web of Science ®Google Scholar
• Morales A. Treatment of carcinoma in situ of the bladder with BCG. A phase II trial. Cancer Immunol Immunother 1980; 9: 69–72.
   Web of Science ®Google Scholar
• Mydlo JH, et al. Retrospective study of efficacy of intravesical BCG alone in treatment of superficial bladder cancer. Urology 1986; 28: 173–175.
   PubMedGoogle Scholar
• Schellhammer PF, et al. Bacillus Calmette-Guérin for superficial transitional cell carcinoma of the bladder. J Urol 1986; 135: 261–264.
   PubMed Web of Science ®Google Scholar
• Soloway MS, Perry A. Bacillus Calmette-Guérin for treatment of superficial transitional cell carcinoma of the bladder in patients who have failed Thiothepa and/or Mitomycin-C. J Urol 1987; 137: 871–873.
   PubMedGoogle Scholar
• Steg A, et al. Oue peut-on attendre de la BCG-thérapie dans le traitement des tumeurs superficielles de vessie. Médecine et Hygiène, 1987; 45: 3397–3400.
   Google Scholar
• Cumming JA, Hargreave TB, Webb J, et al. Intravesical Evans BCG in the treatment of carcinoma in situ. Br J Urol 1989; 63: 259–263.
   PubMedGoogle Scholar
• Bretton P, Herr H, Whitmore W, et al. Intravesical BCG therapy for in situ TCC involving the prostatic urethra. J Urol 1989; 141: 853–856.
   PubMedGoogle Scholar
• Barnes RW, Dick AL, Hadley HL, Johnson O. Survival following transurethral resection of bladder carcinoma. Cancer Res 1977; 37: 2895.
   PubMed Web of Science ®Google Scholar
• Cox CE, Cass AS, Boyce WH. Bladder Cancer: a 26 year review. Trans Am Assoc Genitourin Surg, 1968; 60: 2230.
   Google Scholar
• Flocks RH. Treatment of patients with carcinoma of the bladder. JAMA 1951; 145: 295–301.
   PubMedGoogle Scholar
• Greene, Hanash K, Farrow G. Benign papilloma or papillary carcinoma of the bladder? J Urol 1973; 110: 205.
   PubMed Web of Science ®Google Scholar
• Pyrah L, Raper F, Thomas G. Report of a follow-up of papillary tumors of the bladder. Br J Urol 1973; 45: 84.
   PubMedGoogle Scholar
• Williams J, Hammonds J, Saunders N. Tl Bladder Tumors. Br J Urol 1977; 49: 663.
   PubMedGoogle Scholar
• Denis L, Bouffioux C, Kurth KH, et al. Current status of intravesical chemotherapy trials in the EORTC urological group. An overview. Cancer Chemother Pharmacol 1987; suppl 20: 67–71.
   PubMedGoogle Scholar
• Kurth KH, Denis L, Bouffioux C, et al. Rezidivprophylaxe oberflächlicher Harnblasenkarzinome. Ergebnisse der EORTC genito-urinary group. Urologische Onkologie 1, 1987; 55–72.
   Google Scholar
• Newling D. Intravesical therapy in the management of superficial transitional cell carcinoma of the bladder: the experience of the EORTC GU group. Br J Cancer 1990; 61: 497–499.
   PubMedGoogle Scholar
• Schulman C, Robinson M, Denis L, Smith P, Viggiano G, De Pauw M, Dalesio O, Sylvester R, Members of the EORTC Genito-Urinary Tract Cancer Cooperative Group. Prophylactic chemotherapy of superficial transitional cell bladder carcinoma: an EORTC randomized trial comparing Thiotepa, and epipodophyllotoxin (VM 26) and TUR alone. Eur Urol 1982; 8: 207–212.
   PubMed Web of Science ®Google Scholar
• Dalesio O, Schulman C, Sylvester R, De Pauw M, Robinson M, Denis L, Smith P, Viggiano G, Members of the Genito Urinary Tract Cooperative Group. Prognostic factors in superficial bladder tumors: a study of the EORTC Genito-Urinary Tract Cooperative Group. J Urol 1983; 129: 730–733.
   PubMed Web of Science ®Google Scholar
• Denis L. Anaphylactic reaction to repeated intravesical instillation cisplatin. Lancet I: 1983: 1378.
   Google Scholar
• Kurth KH, Debruvne F, Senge T, Carpentier P, Riedl H, Sylvester R, De Pauw M, EORTC GU Group. Adjuvant cheomotherapy for transitional superficial cell carcinoma of the bladder: an EORTC randomized study comparing doxorubicin hydrochloride, ethoglucid and TUR alone. In: Schröder F, Richards B (eds) EORTC GU Group Monograph 2, part B: Superficial Bladder Tumors. Alan R Liss, New York, 1985; 135.
   Google Scholar
• Debruyne F, van der Meyden A, Schreinecres L, et al. BCG RIVM intravesical immunoprophylaxis for superficial bladder cancer. In: Progress and controversies in oncological urology, II, EORTC GU Monograph No V, Schröder, Klijn, Kurth, Pinedo, Splinter, de Voogt (eds), p 511, Alan R Liss, New York, 1988.
   Google Scholar
• Van der Meyden A. Personal communication 1990.
   Google Scholar
• Martinez-Pineiro J, Jimenez LJ, Martinez-Pineiro Jr L, et al. Intravesical therapy comparing BCG, Adriamycin and Thiotepa in 200 patients with superficial bladder cancer: a randomized prospective study. In: EORTC GU group Monograph 6: BCG in Superficial Bladder Cancer, Alan R Liss Inc, New York, 1989; 237–252.
   Google Scholar
• Lamm D, Crissmann J, Blumenstein B, et al. Adriamycin versus BCG in superficial bladder cancer: a Southwest Oncology group study. In: EORTC GU group Monograph 6: BCG in Superficial Bladder Cancer, Alan R Liss Inc, New York, 1989; 263–270.
   Google Scholar
• Rintala E, Jauhiainen K, Alfthan O, The Finnbladder Research group. Mitomycin-C and BCG in intravesical chemotherapy and immunotherapy of superficial bladder cancer. EORTC GU group Monograph 6, Alan R Liss, New York, 1989; 271–274.
   Google Scholar
• Sylvester R. Prognostic factors from EORTC GU trials 30782 and 30790. Unpublished results. 1990.
   Google Scholar